-
2024-516300-41-00
5
2023-03-07
Multiple Myeloma
-
2023-504540-33-00
5
2023-03-06
COVID-19
-
2024-510590-14-00
5
2023-03-03
multiple myeloma
-
2024-512451-20-00
10
2023-02-28
Patients with biopsy-proven virus-negative inflammatory dilated or non
-
2022-501184-41-00
6
2023-02-13
atopic dermatitis/eczema
-
2022-501426-38-00
4
2023-02-09
Lipoprotein Disorder
-
2024-512258-91-00
5
2023-02-03
Generalized Myasthenia Gravis (gMG)
-
2023-506931-13-00
5
2023-01-30
Overweight and obesity and type 2 diabetes
-
2023-503793-20-00
5
2023-01-18
Prevention of ischemic stroke in patients post acute non-cardioembolic
-
2023-504238-23-00
5
2023-01-17
Hepatitis B, Chronic
-
2022-500186-27-00
5
2023-01-11
ATTR Amyloidosis
-
2023-510195-31-00
4
2023-01-03
Idiopathic or Diabetic Gastroparesis
-
2024-514975-16-00
4
2022-12-22
Non-infectious, Intermediate-, Posterior- or Pan-uveitis
-
2024-515185-13-00
5
2022-12-21
geographic atrophy
-
2022-500652-37-00
4
2022-12-01
Advanced melanoma refractory to prior checkpoint inhibitor therapy
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2022-503144-40-00
5
2022-11-17
Pneumococcal disease
-
2024-514714-12-00
10
2022-11-11
Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-506193-12-00
4
2022-11-10
Newly Diagnosed Medulloblastoma
-
2023-503529-20-00
4
2022-10-17
BRCA Mutations and Early Stage HER2-Negative Breast Cancer
-
2024-512803-37-00
5
2022-10-05
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
-
2024-514788-24-00
5
2022-09-20
Chronic stable plaque psoriasis
-
2023-505458-16-00
5
2022-09-13
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
-
2024-513992-42-00
10
2022-09-13
venous thromboembolism (VTE) in patients with gastrointestinal/genitou